Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers

Lymphoma Clinical Trial

Official title:

Aggressive Non-Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01639716
• Other study ID #: NG63900
• Secondary ID: NG6420NG6420
• Status: Completed
• Phase: N/A
• First received: July 4, 2012
• Last updated: July 12, 2012
• Start date: May 2011
• Est. completion date: June 2012

Study information

• Verified date: July 2012
• Source: Guler, Nil, M.D.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ondokuz Mayis local ethic committee
• Study type: Observational

Clinical Trial Summary

The investigators hypothesized that Non Hodgkin lymphoma is using T helper 2 pathways. So that the investigators decided to study of cytokines related to T helper 2 pathways. It is well known that parasites and allergic situations also use T helper 2 pathways. Because that the investigators excluded the patients have parasites and allergic situations. All the patients were over 18. The investigators included the patients with non Hodgkin lymphoma which new diagnosed. It is observational study. The investigators took blood before chemotherapy and four months later. The investigators did not interfere with which chemotherapy will be given to patients. This decision was belong to hematologist or oncologist who will treat the patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: June 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• newly diagnosed non hodgkin lymphoma

• Diffuse large B cell lymphoma and T cell lymphoma patients

Exclusion Criteria:

• under 18 age

• parasitosis

• allergic status

Study Design

N/A

Related Conditions & MeSH terms

• Lymphoma

Locations

Country	Name	City	State
Turkey	Ondokuz Mayis University Medical School	Samsun	Atakum

Sponsors (1)

Lead Sponsor	Collaborator
Nil Guler

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Interleukin 4 and Interleukin 10 levels as pg/mL in non hodgkin lymphoma	We will measure 31 patients and 27 healthy person's Interleukin 4 and Interleukin 10 levels as pg/mL at the beginning of the study. We determined all of the patients IPI score, LDH (U/L), crp (mg/L), erythrocyte sedimentation rate, hemoglobin (gr/dL), lymphocyte count in per µL, albumin (gr/dL) before the treatment. We wanted to check whether there is any correlation between well known prognostic markers (LDH, crp, albumin, stage, ECOG performance status) and Interleukin-4 and interleukin-10 levels.	This study ended within 13 months	No
Secondary	survey as months	Our secondary goal was to determine the survey time as month from diagnoses to die from any reason or last evaluation during our study which was 13 months.	During study which was 13 months	No

External Links

•   OMU School of Medicine. Contact via e-mail.